TSC22D3 and neoplasm: Thus, in the tumor microenvironment, where GILZ could be upregulated in macrophages or DCs by immunosuppressive lymphokines such as IL-1016, the tolerogenic antigen-presenting cell phenotype may induce not only tumor-specific T-cell inhibition but also Treg cell activity.